Cell News and Research

RSS

Genes role in protecting intestinal tract from colitis may lead to potential targets for treatment

Scientists report a protein made by a gene already associated with a handful of human inflammatory immune diseases plays a pivotal role in protecting the intestinal tract from colitis.

19 Mar 2010

Study shows that steroids target hemangioma stem cells

Hemangiomas -- strawberry-like birthmarks that commonly develop in early infancy - are generally harmless, but up to 10 percent cause tissue distortion or destruction and sometimes obstruction of vision or breathing. Since the 1960s, problematic hemangiomas have been treated with corticosteroids such as dexamethasone or prednisone.

19 Mar 2010

Researchers use optogenetics technology to troubleshoot neural circuits

Recently, brain researchers have gained a powerful new way to troubleshoot neural circuits associated with depression, Parkinson's disease and other conditions in small animals such as rats. They use an optogenetics technology, invented at Stanford University, that precisely turns select brain cells on or off with flashes of light. Although useful, the optogenetics tool set has been limited.

19 Mar 2010

Stemedica files IND for trial using allogeneic mesenchymal bone marrow cells in patients with ischemic stroke

Stemedica Cell Technologies, Inc. (Stemedica), a world leader in stem cell research and manufacturing, announced that it has filed an Investigative New Drug (IND) application with the U.S. Food and Drug Administration (FDA) for a clinical trial. The trial will assess the safety, tolerability and efficacy of Stemedica's high potency proprietary allogeneic mesenchymal bone marrow-derived stem cells (adult human) as a treatment for ischemic stroke.

19 Mar 2010

Robertson Foundation commits $10.2M for Duke Medicine's cell therapy research

A $10.2 million commitment from the Robertson Foundation to create a state-of-the-art Translational Cell Therapy Center (TCTC) will advance Duke Medicine's pioneering cell therapy research and treatment programs for children and adults with cancer, cerebral palsy, stroke and brain injuries suffered at birth.

19 Mar 2010

FDA drafts new rules for testing, approving drug cocktails; Public-private partnership for TB treatment development launched

The FDA is drafting new guidelines for testing and approving multidrug cocktails for life-threatening diseases, the Wall Street Journal reports. "Many diseases, such as AIDS, tuberculosis and cancer, require multidrug combinations. Such drug cocktails can prevent the development of drug resistance, because the microbe or cancer cell needs to undergo more mutations to escape several drugs than to escape just one. By attacking the disease in different ways, drug combinations also improve the chances of therapeutic benefit," the newspaper reports (Schoofs, 3/18).

19 Mar 2010

Interfering with dickkopf 1 protein may help in controlling inflammatory bowel diseases

Signals released by immune cells during a bout of inflammatory bowel disease interfere with intestinal cells' ability to regenerate. Yet people with inflammatory bowel diseases have a significantly higher risk of developing colon cancer: a hyper-activation of growth in those same intestinal cells.

19 Mar 2010

Three scientists receive 2010 Discoverers Award for developing new class of HIV drug

Three scientists who led the 11-year quest to develop a groundbreaking HIV drug today received the 2010 Discoverers Award -- the highest honor given to scientists by the Pharmaceutical Research and Manufacturers of America. The honorees are Tony Wood, Ph.D., Elna van der Ryst, M.D., Ph.D. and Manos Perros, Ph.D.

19 Mar 2010

ASCO Scientific Program 2010: Provectus Pharmaceuticals' Phase 2 data on PV-10 accepted for presentation

Provectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, announced today that data from its Phase 2 study of PV-10 for metastatic melanoma has been accepted for presentation at the 2010 American Society of Clinical Oncology (ASCO) Scientific Program to be held on June 4 – 8, 2010 in Chicago, Illinois.

19 Mar 2010

Survey unveils impact of gene regulation on human health

Researchers are only beginning to understand how individual variation in gene regulation can have a lasting impact on one's health and susceptibility to certain diseases. Now, an ambitious survey of the human genome has identified differences in the binding of master regulators called transcription factors to DNA that affect how genes are expressed in different people.

19 Mar 2010

Call for European Cystic Fibrosis healthcare gap to be closed

A healthcare gap amounting to a ‘death sentence’ for Cystic Fibrosis (CF) children born in Eastern Europe must be closed say researchers from the EuroCareCF Coordination Action for Cystic Fibrosis.

18 Mar 2010

Acne drug prevents HIV breakout

Johns Hopkins scientists have found that a safe and inexpensive antibiotic in use since the 1970s for treating acne effectively targets infected immune cells in which HIV, the virus that causes AIDS, lies dormant and prevents them from reactivating and replicating.

18 Mar 2010

Stiff skin syndrome cause found

By studying the genetics of a rare inherited disorder called stiff skin syndrome, researchers at the Johns Hopkins University School of Medicine have learned more about scleroderma, a condition affecting about one in 5,000 people that leads to hardening of the skin as well as other debilitating and often life-threatening problems. The findings, which appear this week in Science Translational Medicine, open doors to testing new treatments.

18 Mar 2010

Malvern image analysis system measures sub-visible particulates in biotherapeutics

Specialists at Malvern Panalytical have demonstrated the application of dynamic particle image analysis to the measurement of sub-visible particulates in biological therapeutics, using the Sysmex FPIA-3000 particle characterization system.

From Malvern Panalytical 18 Mar 2010

Proteacel acquires exclusive rights to PORE technology from Moffitt Cancer Center

Moffitt Cancer Center and Proteacel LLC announced today that they have entered a licensing agreement under which Proteacel has acquired the exclusive rights to the PORE™ technology for delivery of genes into cells.

18 Mar 2010

Genocea Biosciences acquires global license for novel Streptococcus pneumoniae antigens from Children’s Hospital Boston

Genocea Biosciences, a vaccine discovery and development company, today announced an exclusive worldwide license for developed countries to a portfolio of Streptococcus pneumoniae antigens from Children’s Hospital Boston. PATH and Genocea retain certain co-exclusive rights to the antigens for use in developing countries under their collaboration agreements with Children's Hospital Boston.

18 Mar 2010

ISCO commences second phase of testing RPE derived from parthenogenetic stem cells

International Stem Cell Corporation, announced today that ISCO's Research and Therapeutic Development Group, together with a group of scientists from the University of California, Irvine (UCI), is starting a second phase of essential pre-clinical experiments to test retinal pigment epithelium derived from parthenogenetic stem cells. Follow on pre-clinical experiments will be conducted to rescue vision in disease models.

18 Mar 2010

StemCells granted UK patent covering true rat stem cells and genetically engineered rats

StemCells, Inc. announced today that the United Kingdom (UK) Intellectual Property Office has granted patent number GB2451523 with broad claims covering true (germline competent) rat stem cells and genetically engineered rats derived from these cells. The patented technology is expected to have significant utility to academic and pharmaceutical industry researchers by enabling them to create novel rat models for the study of human diseases. Both mice and rats are used by scientists to model various human diseases.

18 Mar 2010

Novelos Therapeutics Phase 3 trial of NOV-002 in advanced NSCLC fails to meet primary and secondary endpoints

Novelos Therapeutics, Inc., a biopharmaceutical company focused on the development of therapeutics to treat cancer and hepatitis, today announced that primary and secondary endpoints were not met in Novelos’ pivotal Phase 3 trial in advanced non-small cell lung cancer (NSCLC) with its lead product, NOV-002, in combination with first-line chemotherapy.

18 Mar 2010

ZIOPHARM Oncology reports fourth quarter net income of $1.0M against loss last year

ZIOPHARM Oncology, Inc., a biopharmaceutical company that is seeking to develop and commercialize a diverse, risk sensitive portfolio of in-licensed cancer drugs addressing unmet medical needs, announced today its financial results for the fourth quarter and full year 2009, and the filing of its Annual Report on Form 10-K with the Securities and Exchange Commission.

18 Mar 2010

Cell News and Research

Genes role in protecting intestinal tract from colitis may lead to potential targets for treatment

Study shows that steroids target hemangioma stem cells

Researchers use optogenetics technology to troubleshoot neural circuits

Stemedica files IND for trial using allogeneic mesenchymal bone marrow cells in patients with ischemic stroke

Robertson Foundation commits $10.2M for Duke Medicine's cell therapy research

FDA drafts new rules for testing, approving drug cocktails; Public-private partnership for TB treatment development launched

Interfering with dickkopf 1 protein may help in controlling inflammatory bowel diseases

Three scientists receive 2010 Discoverers Award for developing new class of HIV drug

ASCO Scientific Program 2010: Provectus Pharmaceuticals' Phase 2 data on PV-10 accepted for presentation

Survey unveils impact of gene regulation on human health

Call for European Cystic Fibrosis healthcare gap to be closed

Acne drug prevents HIV breakout

Stiff skin syndrome cause found

Malvern image analysis system measures sub-visible particulates in biotherapeutics

Proteacel acquires exclusive rights to PORE technology from Moffitt Cancer Center

Genocea Biosciences acquires global license for novel Streptococcus pneumoniae antigens from Children’s Hospital Boston

ISCO commences second phase of testing RPE derived from parthenogenetic stem cells

StemCells granted UK patent covering true rat stem cells and genetically engineered rats

Novelos Therapeutics Phase 3 trial of NOV-002 in advanced NSCLC fails to meet primary and secondary endpoints

ZIOPHARM Oncology reports fourth quarter net income of $1.0M against loss last year

Industry Focus eBook - Cell & Gene Therapy (1st Edition) eBook

Latest eBooks

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo